-
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
•
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed. About AbcamAbcam is…
